Guo Xinzhe, Ou Tong, Yang Xinyu, Song Qi, Zhu Lin, Mi Shengquan, Zhang Jing, Zhang Yanzhen, Chen Wen, Guo Junxia
Beijing Key Laboratory of Bioactive Substances and Functional Foods, Beijing Union University, Beijing, China.
China National Center for Food Safety Risk Assessment, Beijing, China.
Front Nutr. 2024 Apr 19;11:1367589. doi: 10.3389/fnut.2024.1367589. eCollection 2024.
Taurine has a prominent lipid-lowering effect on hyperlipidemia. However, a comprehensive analysis of the effects of taurine on endogenous metabolites in hyperlipidemia has not been documented. This study aimed to explore the impact of taurine on multiple metabolites associated with hyperlipidemia.
The hyperlipidemic mouse model was induced by high-fat diet (HFD). Taurine was administered via oral gavage at doses of 700 mg/kg/day for 14 weeks. Evaluation of body weight, serum lipid levels, and histopathology of the liver and adipose tissue was performed to confirm the lipid-lowering effect of taurine. Ultra-high performance liquid chromatography-mass spectrometry (UPLC-MS)-based metabonomics analyses of serum, urine, feces, and liver, coupled with multivariate data analysis, were conducted to assess changes in the endogenous metabolites.
Biochemical and histological examinations demonstrated that taurine administration prevented weight gain and dyslipidemia, and alleviated lipid deposition in the liver and adipose tissue in hyperlipidemic mice. A total of 76 differential metabolites were identified by UPLC-MS-based metabolomics approach, mainly involving BAs, GPs, SMs, DGs, TGs, PUFAs and amino acids. Taurine was found to partially prevent HFDinduced abnormalities in the aforementioned metabolites. Using KEGG database and MetaboAnalyst software, it was determined that taurine effectively alleviates metabolic abnormalities caused by HFD, including fatty acid metabolism, sphingolipid metabolism, glycerophospholipid metabolism, diacylglycerol metabolism, amino acid metabolism, bile acid and taurine metabolism, taurine and hypotaurine metabolism. Moreover, DGs, GPs and SMs, and taurine itself may serve as active metabolites in facilitating various anti-hyperlipidemia signal pathways associated with taurine. This study provides new evidence for taurine to prevent hyperlipidemia.
牛磺酸对高脂血症具有显著的降脂作用。然而，尚未有关于牛磺酸对高脂血症内源性代谢物影响的全面分析报道。本研究旨在探讨牛磺酸对与高脂血症相关的多种代谢物的影响。
通过高脂饮食（HFD）诱导建立高脂血症小鼠模型。以700毫克/千克/天的剂量经口灌胃给予牛磺酸，持续14周。评估体重、血清脂质水平以及肝脏和脂肪组织的组织病理学，以确认牛磺酸的降脂效果。采用基于超高效液相色谱-质谱联用（UPLC-MS）的代谢组学方法对血清、尿液、粪便和肝脏进行分析，并结合多变量数据分析，以评估内源性代谢物的变化。
生化和组织学检查表明，给予牛磺酸可防止高脂血症小鼠体重增加和血脂异常，并减轻肝脏和脂肪组织中的脂质沉积。通过基于UPLC-MS的代谢组学方法共鉴定出76种差异代谢物，主要涉及胆汁酸、甘油磷脂、鞘脂、二酰甘油、三酰甘油、多不饱和脂肪酸和氨基酸。发现牛磺酸可部分预防HFD诱导的上述代谢物异常。利用KEGG数据库和MetaboAnalyst软件确定，牛磺酸可有效缓解由HFD引起的代谢异常，包括脂肪酸代谢、鞘脂代谢、甘油磷脂代谢、二酰甘油代谢、氨基酸代谢、胆汁酸和牛磺酸代谢、牛磺酸和亚牛磺酸代谢。此外，二酰甘油、甘油磷脂和鞘脂以及牛磺酸本身可能作为活性代谢物，促进与牛磺酸相关的各种抗高脂血症信号通路。本研究为牛磺酸预防高脂血症提供了新的证据。
